For help on how to get the results you want, see our search tips.
2 results
Medicine type
Generic Remove Generic filter
Accelerated assessment Remove Accelerated assessment filter
Additional monitoring Remove Additional monitoring filter
Orphan medicine Remove Orphan medicine filter
Exceptional circumstances Remove Exceptional circumstances filter
Medicine
Referrals Remove Referrals filter
Summaries of opinion Remove Summaries of opinion filter
Direct healthcare professional communication Remove Direct healthcare professional communication filter
Referral authorisation model
Centrally authorised product(s) Remove Centrally authorised product(s) filter
Centrally and nationally authorised products (mixed) Remove Centrally and nationally authorised products (mixed) filter
Referral PRAC recommendation
Risk minimisation measures Remove Risk minimisation measures filter
Referral safety status
Yes Remove Yes filter
-
List item
Referral: Quinolone- and fluoroquinolone-containing medicinal products
nalidixic acid, pipemidic acid, cinoxacin, enoxacin, pefloxacin, lomefloxacin, ciprofloxacin, levofloxacin, ofloxacin, moxifloxacin, norfloxacin, prulifloxacin, rufloxacin, flumequin, associated names: Quinsair, Article 31 referrals
Status: European Commission final decision, opinion/position date: 15/11/2018, EC decision date: 11/03/2019, Last updated: 19/03/2019 -
List item
Referral: Lemtrada
alemtuzumab, associated names: Lemtrada, Article 20 procedures
Status: European Commission final decision, opinion/position date: 14/11/2019, EC decision date: 16/01/2020, Last updated: 04/02/2020